Edition:
United Kingdom

People: Aquestive Therapeutics Inc (AQST.OQ)

AQST.OQ on NASDAQ Stock Exchange Global Market

3.81USD
23 Jul 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.81
Open
$3.86
Day's High
$3.90
Day's Low
$3.75
Volume
24,127
Avg. Vol
44,542
52-wk High
$19.80
52-wk Low
$3.68

Maxwell, John 

Mr. John T. Maxwell is Senior Vice President – Chief Financial Officer of the Company since January 2017. Prior to joining our team, Mr. Maxwell held senior financial roles at WIL Research, InfoNXX, PanAmSat, ADP and General Signal, including as Chief Financial Officer of WIL Research from September 2008 to April 2016. In addition, Mr. Maxwell served as a freelance consultant from April 2016 until January 2017. Mr. Maxwell started his career at Ernst & Young, serving in the Dallas, New York and Stamford offices. Mr. Maxwell helped lead the successful strategic sale transactions by the private equity sponsors of WIL Research in April 2016 to Charles River Labs and of PanAmSat in 2006 to Intelsat. Mr. Maxwell also helped lead the initial public offering of PanAmSat in 2005 and multiple public and private debt transactions for WIL Research, InfoNXX and PanAmSat. Mr. Maxwell is a licensed certified public accountant and holds a BBA in Accounting from Texas Tech University and an MBA in Finance and International Business from New York University Stern School of Business.

Basic Compensation

Total Annual Compensation, USD 726,250
Restricted Stock Award, USD 874,335
Long-Term Incentive Plans, USD --
All Other, USD 19,615
Fiscal Year Total, USD 1,620,200

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --